RemeGen

Asia
Biotech

RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen for $34.8 million upfront.
James Waldron Aug 19, 2025 7:18am
A one dollar bill sitting next to a declining stock graph
Favicon Fierce Pharma

Vor Bio's surprise $4B revival deal splits investor reactions

Jun 26, 2025 10:55am
Hong Kong

RemeGen grabs one of the world's largest ever biotech IPOs

Nov 9, 2020 7:58am